Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children - Wikidata - wikimedia - TriplyDB

Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children

Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children

http://www.wikidata.org/entity/Q24241860

about

Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders Antifibrinolytic therapy to reduce haemoptysis from any cause Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders Anti-fibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis Improving perioperative care for adolescent idiopathic scoliosis patients: the impact of a multidisciplinary care approach Antifibrinolytic therapy to reduce haemoptysis from any cause.A prospective, randomized, double-blinded single-site control study comparing blood loss prevention of tranexamic acid (TXA) to epsilon aminocaproic acid (EACA) for corrective spinal surgery.Tranexamic acid for treatment and prophylaxis of bleeding and hyperfibrinolysis.Metabolomic profile and nucleoside composition of Cordyceps nidus sp. nov. (Cordycipitaceae): A new source of active compounds.Efficacy of tranexamic acid in reducing blood loss in posterior lumbar spine surgery for degenerative spinal stenosis with instability: a retrospective case control study.Safety and efficacy of caproamin fides and tranexamic Acid versus placebo in patients undergoing coronary artery revascularization Intraoperative blood loss in female patients with adolescent idiopathic scoliosis during different phases of the menstrual cycle Use of tranexamic acid for controlling bleeding in thoracolumbar scoliosis surgery with posterior instrumentation Efficacy of tranexamic acid in reducing allogeneic blood products in adolescent idiopathic scoliosis surgery.Use of Tranexamic Acid (TXA) on reducing blood loss during scoliosis surgery in Chinese adolescents.A Comparison of Two Different Dosing Protocols for Tranexamic Acid in Posterior Spinal Fusion for Spinal Deformity: A Prospective, Randomized Trial.Pulmonary complications after spine surgery.Coagulopathy after severe pediatric trauma Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children.Efficacy and safety of tranexamic acid in reducing blood loss in scoliosis surgery: a systematic review and meta-analysis.Risk factors for intraoperative allogeneic blood transfusion during craniotomy for brain tumor removal in children.Management of Dilutional Coagulopathy during Pediatric Major Surgery.Temporary inhibition of the plasminogen activator inhibits periosteal chondrogenesis and promotes periosteal osteogenesis during appendicular bone fracture healing.Guidelines on transfusion for fetuses, neonates and older children.Treatment massive haemoptysis in cystic fibrosis with tranexamic acid.

P2860

Q24186028-66503213-61C7-4FD4-BBAD-1643C5316226 Q24200405-E520648A-2244-4230-9B4A-0E177ADF0442 Q24201018-D1E93669-8660-40B2-9452-F6F6F3C3CB91 Q24201514-401269E6-F1CE-4875-AACB-3D0D887975B5 Q26864678-5ACA4746-2415-4F30-99C1-F7FA6D306C11 Q28073473-1E8FB472-14FB-4E5E-AAF2-EEF3FD0B06F8 Q30241963-6D7B6C9B-5A3C-4E87-8446-D51151181D35 Q33549947-0FEBF995-593A-4611-9CB0-CC007676F283 Q33676496-DD859C65-BCBE-4917-B669-29D7F39AD435 Q33821837-C5074215-BD6E-486C-97D5-C06AFD5DC6DA Q34065040-21C6F579-4A5F-4BCE-82E4-C5151BDB6E85 Q34333498-CD29917B-7EF7-4703-AC79-9CDD404CA79D Q34571870-19665727-1EDC-4ED4-B9E5-0DB1626079FE Q35901800-B7968F78-A3CC-45B4-9DB9-C528459D15E3 Q36000125-0014D0E5-36F9-4510-AE8F-F58A506F518D Q36120681-95B849F7-35B0-43D0-BF9F-475BBAB7F7F4 Q36455146-D7A149C1-16BF-457C-89E0-038A71E8464C Q36508025-50754129-10C7-435C-A4BF-CE358B8F34C7 Q38191128-1907A2A7-9951-43BD-9ED6-7D99485991B0 Q38958444-6D1D381E-0E30-4158-96C8-23310674C3E1 Q39024167-F56704D8-A35F-49B9-8437-B0176A9E3125 Q40316436-DFE1E83C-04E4-443D-9B1E-905E7AE73752 Q41927430-5C4CC006-C5C6-4704-A1F8-48AEFA7389DA Q52572516-4E5F682D-8A16-4332-9FAF-FE960071DD43 Q53674609-4D0E9C97-E7B7-4E7D-8958-B267D0A39F47 Q55176546-4B41E5A4-8D90-4C9D-A8D0-8782B7E407F2

P2860

Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children

http://www.wikidata.org/entity/Q24241860

description

2008 nî lūn-bûn

@nan

2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children

@ast

Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children

@en

Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children

@en-gb

Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children

@nl

type

label

Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children

@ast

Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children

@en

Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children

@en-gb

Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children

@nl

prefLabel

Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children

@ast

Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children

@en

Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children

@en-gb

Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children

@nl

P1433

Q24241860-5EAD09DF-28E9-45E4-B754-78B38077B5BF

P1476

Q24241860-460121C6-3F66-4F79-BD46-09382A6D6EC6

P2093

Q24241860-6D967337-C573-421E-A269-7E651DD4E5D0

Q24241860-E6CB8C7D-AD73-4370-B561-EF08A950938A

Q24241860-FB394F03-5276-438E-8A4B-34A533F1C5D0

Q24241860-FDF3D018-6768-4EE0-9E47-E3249BC090C1

P2860

Q24241860-06D8E5F9-D2F4-46CF-BC13-C35510E5BBE5

Q24241860-0728B48C-8C5D-4F22-AE83-218664C288BB

Q24241860-0739AE75-92F7-4A8F-91A0-E0F05DEAF5D8

Q24241860-0E5523EC-DAEA-4E53-A795-92B747023610

Q24241860-1873EDD6-0B4B-4DFA-8450-921BE34A8DC5

Q24241860-2B3D68C2-7BCD-43AA-AD2C-21828B4BD727

Q24241860-32CC9C53-0E3C-4C7A-80FA-0876A493CF12

Q24241860-351268A3-C880-44D8-BC22-98A1BB90CAFE

Q24241860-598BE02E-E142-4215-9FFD-88CD8F532850

Q24241860-59F2AA16-2D92-4346-9D46-BE6F49BCEB77

P31

Q24241860-B97403B0-3CC5-497C-8768-D2C60788E77A

Q24241860-e4802ace-9e77-4a61-9c4a-b6496e3ebd00

P3181

Q24241860-DC66D307-5CD1-488E-BA16-3DA56BCEA103

P356

Q24241860-098A01D9-C6FB-4D67-A8C5-75AA1934A152

P577

Q24241860-DD06C7CC-4B54-4269-884B-7A2E4AF89E16

P698

Q24241860-AE9CF686-1475-4447-953B-5EA31410E268

P3181

P356

14651858.CD006883.PUB2

P1433

Cochrane Database of Systematic Reviews

P1476

Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children

@en

P2093

Aikaterini Tzortzopoulou

http://www.w3.org/2001/XMLSchema#string

Daniel B Carr

http://www.w3.org/2001/XMLSchema#string

M Soledad Cepeda

http://www.w3.org/2001/XMLSchema#string

Roman Schumann

http://www.w3.org/2001/XMLSchema#string

P2860

Aprotinin in major orthopedic surgery: a systematic review of randomized controlled trials

Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery

Minimizing perioperative blood loss and transfusions in children.

Pre-operative autologous donation for minimising perioperative allogeneic blood transfusion

Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery.

Predictors of red cell transfusion in children and adolescents undergoing spinal fusion surgery.

The effect of amicar on perioperative blood loss in idiopathic scoliosis: the results of a prospective, randomized double-blind study.

An overview of blood-sparing techniques used in spine surgery during the perioperative period.

Intraoperative pediatric blood transfusion therapy: a review of common issues. Part II: transfusion therapy, special considerations, and reduction of allogenic blood transfusions.

Transfusion safety: Where are we today?

P31

scholarly article

P3181

2063911

http://www.w3.org/2001/XMLSchema#string

P356

10.1002/14651858.CD006883.PUB2

http://www.w3.org/2001/XMLSchema#string

P577

2008-07-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18646174

http://www.w3.org/2001/XMLSchema#string